BioSpark聊biotech news：2024年九月生物医药大事讨论

立即预约直播

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。

本月热点

TOPICS

1. Oncology：

Summit/Akeso’s PD1 X VEGF bispecific antibody Ivonescimab showed PFS benefit over Keytruda in 1L NSCLC phase 3 study;
Biotheus announced phase 2 data of their PD-L1 X VEGF bispecific antibody;
Eli Lilly launched 750-patient phase 1 study for their pan-KRAS inhibitor;
Amgen’s PRMT5 inhibitor AMG193 showed preliminary clinical activity in MTAP-deleted solid tumors;
Astellas provided phase 1 updates on KRAS G12D degrader ASP3082;
BMS launched phase 3 study of anti-PD1 + anti-LAG3 combination therapy in 1L NSCLC;
AstraZeneca / Daiichi’s TROP2-directed ADC failed to improve overall survival in phase 3 trials of breast cancer and NSCLC;

2. Autoimmune Diseases:

Boehringer Ingelheim’s nerandomilast met the primary end point in the pivotal phase 3 FIBRONEER-IPF trial;
UCB & Biogen announced positive topline phase 3 results of Dapirolizumab Pegol in SLE, ready to initiate a second phase 3 study;
Candid Therapeutics debuts with $370M in seed funding and a 3-way merger by acquiring Vignette Bio and TRC 2004;
Amgen announced topline phase 3 data for anti-OX40 in atopic dermatitis;
Organon pays up to $1.2B to acquire Dermavant;

3. Other Topics:

Amgen provided phase 3 updates on their anti-CD19 Uplizna for myasthenia gravis;
Novo Nordisk’s CB1 inverse agonist showed modest results in weight loss, raising concerns of psychiatric side effects.

活动详情

主题：Monthly biotech news discussion – September 2024 in review

时间：2024年09月28日 Sat 9:00 PM（EST）/ 2024年09月29日周日早上9:00 AM（北京时间）

地点：药时代视频号

BioSpark聊biotech news：2024年九月生物医药大事讨论 | 药时代直播间

嘉宾：

Jimmy Wang (王俊), Assistant Professor @ New York University

(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)

Ethan Xu (徐亦迅),VP of Bioinformatics @ Aspen Neuroscience

(http://linkedin.com/in/ethan-yixun-xu-2b915a4)

Yanran He (何嫣然), Investment Director @ Sinopharm-CICC

(https://www.linkedin.cn/injobs/in/yanranhe)

Lihua Yu (于利华), Chief Data Officer @ Fogpharma

(https://www.linkedin.com/in/lihua-yu-5b3337)

Leon ‘Jun’ TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory

(https://www.linkedin.com/in/leontangnyc/)

Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)

Haoran Wang(王浩然), CEO @ Weihai Neoland Biosciences Co.,Ltd.

(https://www.linkedin.com/in/hao-ran-wang-228648b)

Yongjiang Hei (黑永疆), Co-CEO @ Biocity Biopharma

( http://linkedin.com/in/yonghei)

Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture

(https://www.linkedin.com/in/文君-吴-14787b95/)

本期活动组织：Ethan Xu & Jimmy Wang

本月热点总结：Armstrong和monthly news嘉宾

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

成为BioSpark会员：BioSpark期待您的加入–会员推荐与申请

https://www.biospark.org/

Follow us on Twitter:
https://twitter.com/BioSpark_Group

Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar:
https://tinyurl.com/tcwy44t6

Email us: info@BioSpark.org

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group